Check for updates

OPEN ACCESS

EDITED BY Giorgio Sandrini, Fondazione Cirna Onlus, Italy

REVIEWED BY Aikeremujiang Muheremu, Sixth Affiliated Hospital of Xinjiang Medical University, China Elias Rizk, Penn State Milton S. Hershey Medical Center, United States

*CORRESPONDENCE Heng-Zhu Zhang ⊠ zhanghengzhu@sina.com

RECEIVED 01 December 2022 ACCEPTED 03 August 2023 PUBLISHED 17 August 2023

CITATION

Luo W, Yan Z, Guo Y, Xu J and Zhang H-Z (2023) Contralateral seventh cervical nerve transfer for central spastic arm paralysis: a systematic review and meta-analysis. *Front. Neurol.* 14:1113254. doi: 10.3389/fneur.2023.1113254

COPYRIGHT

© 2023 Luo, Yan, Guo, Xu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Contralateral seventh cervical nerve transfer for central spastic arm paralysis: a systematic review and meta-analysis

WenMiao Luo^{1,2}, ZhengCun Yan², Yu Guo², Ji Xu^{1,2} and Heng-Zhu Zhang^{1,2}*

¹Northern Jiangsu People's Hospital, Yangzhou, China, ²Department of Neurosurgery, The Yangzhou School of Clinical Medicine of Dalian Medical University, Yangzhou, China

Objectives: The specific benefits of a contralateral cervical 7 nerve transplant in people with spastic paralysis of the upper extremity caused by cerebral nerve injury are unclear. To evaluate the efficacy and safety of contralateral C7 nerve transfer for central spastic paralysis of the upper extremity, we conducted a comprehensive literature search and meta-analysis.

Materials and methods: PRISMA guidelines were used to search the databases for papers comparing the efficacy of contralateral cervical 7 nerve transfer vs. rehabilitation treatment from January 2010 to August 2022. The finishing indications were expressed using SMD \pm mean. A meta-analysis was used to assess the recovery of motor function in the paralyzed upper extremity.

Results: The meta-analysis included three publications. One of the publications offers information about RCTs and non-RCTs. A total of 384 paralyzed patients were included, including 192 who underwent CC7 transfer and 192 who received rehabilitation. Results from all patients were combined and revealed that patients who had CC7 transfer may have regained greater motor function in the Fugl-Meyer score (SMD 3.52, 95% CI = 3.19-3.84, p < 0.00001) and had superior improvement in range of motion compared to the rehabilitation group (SMD 2.88, 95% CI = 2.47-3.29, p < 0.00001). In addition, the spasticity in the paralyzed upper extremity significantly improved in patients with CC7 transfer (SMD -1.42, 95% CI = -1.60 to -1.25, p < 0.00001).

Conclusion: Our findings suggested that a contralateral C7 nerve transfer, which has no additional adverse effects on the healthy upper limb, is a preferable method to restore motor function.

KEYWORDS

meta-analysis, rehabilitation therapy, recovery, stroke, surgery

Introduction

The clinical incidence of cerebral hemorrhage, cerebral infarction, and traumatic brain injury-induced central spastic paralysis of the upper limbs has gone up recently. From 1990 to 2019, the absolute number of stroke incidents worldwide grew by 70% (67%–73%). As a result of falls, both the number and rate of TBI-related hospitalizations rose among those under 75 years old (from 356.9 in 2007 to 454.4 in 2013 per 100,000 population) (1, 2). Limb paralysis

brought on by central nervous system damage was a widespread issue that has a significant negative impact on patients, their families, and society (3, 4). Previous therapies including transcranial magnetic stimulation and hyperbaric oxygen therapy aimed to heal the damaged central nervous system, but the outcomes were often subpar over the long run. One of its medical issues is how to better restore the wounded upper limb's functionality (5).

Brachial plexus nerve injuries were formerly treated using C7 nerve transposition. Gu et al., inventively used it to cure central upper limb spastic paralysis in 2008 based on considerable theory and tests (6, 7). A transpositional anastomosis was used to join the proximal end of the C7 nerve on the side with paralysis to the distal end of the C7 nerve in the healthy upper limb. Innervation of both upper limbs by the uninjured cerebral hemispheres was accomplished after functional rearrangement of the cerebral hemispheres. It offered a fresh approach to treating spastic arm palsy (8–11).

Numerous research had looked at the healing process of contralateral C7 nerve transfer in the management of central upper limb paresis, however it was unclear if this has any particular advantages (12–14). As a result, we performed a meta-analysis of contralateral C7 nerve transfer for central upper limb spastic palsy based on the body of current research to assess the efficacy of this procedure.

This systematic review and meta-analysis were to: (1) compare the recovery of upper limb motor function in patients with central upper limb paresis in the surgery group to that of the rehabilitation group; (2) evaluate the change in upper limb spasticity status in the surgery group following treatment and compare it to that of the rehabilitation group; and (3) evaluate patient safety following CC7 transfer and the negative effects of nerve disconnect. For example, the impact on the contralateral upper limb's motor and sensory function, the impact on the healthy upper limb's fine mobility during the course of prolonged monitoring, Agony following nerve disconnect or the possibility of postoperative infection and bleeding, etc.

Methods

Standard protocol approvals, registrations, and patient consents

The PROSPERO registry has the research protocol prospectively recorded under Registration. According to the PRISMA statement (Registration No.: CRD42022363569), this systematic review and meta-analysis was conducted, and it was then reported in accordance with the Moose standards. Furthermore, there was no need for ethics in this meta-analysis (15, 16).

Search strategy

Searches were conducted on electronic databases such PubMed, Human Repository, Embase, Web Science, VIP, CNKI, CBM, and WFSD. Articles only from 2010 to the present that were randomly chosen as controls were chosen. MESH (paralysis and upper extremity) and non-MESH (CC7 nerve, seventh cervical nerve, cervical seventh nerve, C7 nerve, cervical 7 nerve, 7 cervical nerve, etc.) keywords were used for searches (specific search formulae are in the Supplementary material). We conducted a manual search to complete all references that matched the included articles or earlier evaluations in order to fight search incompleteness. The qualifying requirements were last checked on August 10, 2022, to make sure that no additional research matched them.

Inclusion criteria and exclusion criteria

The following were the inclusion requirements: (1) participants: individuals with cerebral palsy, traumatic brain injury, hemiplegia following, ischemic stroke, hemorrhagic stroke, or both who also exhibited stiffness and weakness in the upper limb contralateral to the brain damage were eligible to participate (patients receiving regular rehabilitation for at least 1 year prior to admission but showing small functional improvement effects in the upper limb). (2) Outcomes: the Fugl-Meyer upper extremity scale, the modified Ashworth scale, and upper extremity range of motion were used to assess motor function and the degree of spasticity in the afflicted limb. (3) Results: the change in UEFM score between the baseline and follow-up was the main result. Modified Ashworth scale (MAS) and range of motion score change from baseline to follow-up were considered secondary outcomes. Spasticity was measured by the MAS score. (4) Published randomized controlled trials.

The exclusion criteria were as follows: (1) absence of source data (2) participants who had previously had bilateral brain malfunction, mental problems, pregnancy, hemorrhagic shock, life-threatening systemic damage, cardiac arrest, chronic sickness, and past severe illness. (3) The literature included case studies, animal experiments, research techniques that did not include CC7, as well as other indicators of study outcomes.

Study selection

Two impartial examiners (WL. and ZY) in order to find potentially unpublished data, the process is completed by (1) carefully reading the titles and abstracts of all pertinent studies. (2) Manually searching key journals and abstracts of significant annual meetings in the fields of paralysis and CC7 transfer, and (3) contacting experts. The investigators work individually to conduct the majority of the search. Any discrepancies are handled without using the original processes by consulting with the investigators.

Data extraction

Using a pre-made data extraction form, WL and ZY, two reviewers, independently extracted data. Disputes were settled with a third reviewer (YG). First author, study characteristics (such as year and design), participant characteristics (such as age, country, and sample size), methodological features (such as inclusion criteria, detection, and collecting time), and results were among the data that were extracted (i.e., F-M, MAS, ROM). When it was feasible, assessors

Abbreviations: CC7, Contralateral C7 nerve; F-M, Fugl-Meyer upper-extremity scale; MAS, Modified Ashworth scale; ROM, Range of motion; SMDs, Standard mean differences; Cls, Confidence intervals; *I*², I-square.

contacted the principal author of studies with incomplete data to gather and verify the information. The mean and standard deviation values were extracted using GetData Graph Digitalizer2.24¹ if the data is graphically or otherwise represented.

Risk of bias assessment

The quality of the study was reviewed by two impartial assessors. The quality and bias risk of the RCT studies were evaluated using the Cochrane Collaboration's technique for evaluating risk of bias (17). ROBINS-I assessed the quality and risk of bias evaluation of nRCT publications (18). The two areas of offset risk and applicability were examined. Every category has a unique assessment strategy. We categorize the risk of deviation in each area as low, uncertain, or high based on the strategy utilized to guarantee that each kind of deviation is reduced. In the field of methodology, research whose quality is assessed as low-risk (in all areas) is considered to be of high quality. Any differences will be discussed and resolved by the entire review team.

Statistical analysis

Based on the raw data, each outcome indicator for patients undergoing CC7 transfer and rehabilitation was evaluated in each randomized controlled and non-randomized research. Consecutive outcomes assessed on the same scale were represented as means and standard deviations and evaluated using standardized mean deviations (SMDS) with 95% confidence intervals (CI) due to potential discrepancies in how they were measured and/or when they were collected. Additionally, in a meta-analytical subgroup study, each upper extremity site's ROM (elbow, forearm, wrist) and MAS (elbow, forearm, wrist, thumb, fingers 2-4) prognosis was investigated independently. For a pooled examination of the recovery of total motor function in patients who had CC7 transposition, we aggregated all MAS, ROM, and F-M scores. In order to evaluate potential negative effects of CC7 transfer, research data reporting surgical and rehabilitation patients were used to conduct a meta-analysis of adverse events of CC7 in paralyzed patients (risk ratio RR with associated 95% CI). The randomized effect models were selected in accordance with the Cochrane review recommendations if there was significant heterogeneity at p < 0.1 or $I^2 > 50\%$; otherwise, fixed-effect models were utilized. This research comprised less than five publications, and no further sensitivity analysis was carried used (19). The software program Review Manager from the Cochrane Collaboration was used for all statistical calculations (RevMan 5.3). And Feng's et al. (20) nRCT information was eliminated, and outcome indicators were reassessed.

Results

Search results

In accordance with the aforementioned search methodology, 1,119 relevant studies were considered, 19 duplicates were eliminated,

and 1,100 studies remained. One thousand eighty nine papers that did not match the inclusion criteria were removed by reviewing the titles and abstracts. Finally, 3 (20–22) English-language articles were accepted after the remaining 8 non-full-text articles were further eliminated in accordance with the exclusion criteria. The flow diagram of literature screening is shown in Figure 1. Included in Feng's et al. (20) paper were 336 surgical and rehabilitative patients. Seventeen patients in the surgery group and 14 patients in the rehabilitation group met the inclusion criteria for the randomized, controlled trial (refer to the Feng's Supplementary for specifics).

Characteristics of included studies

In the meta-analysis, 384 patients from papers published between 2015 and 2022 were included. The age range of the participants in these researches was 4 to 69. The included studies were RCTs and nRCTs (complete data of Feng are from Supplementary Information). These studies mostly described 192 individuals who had complete rehabilitation and 192 patients who received contralateral C7 nerve grafts. The findings showed that following CC7 transfer, the patients' paralyzed arm had improved motor function and spasticity status. When comparing the two groups at short-term follow-up, it also included the significant negative effects that developed in the surgery group following surgery in comparison to the rehabilitation group. The efficacy and safety of the surgical and rehabilitative groups for treating central upper limb paresis were contrasted in the meta-analysis. Characteristics of included studies were summarized in Table 1.


Quality assessment

In three papers, the risk of deviation and applicability were examined using the Revman5.3 program and the method for measuring bias risk developed by the Cochrane Collaboration. The results of the quality assessment were shown in Figure 2 and Table 2. The three papers' blinding of participants and personnel involved substantial risk for both parties. The three included English literature articles reported cases of central paralysis with preserved consciousness in patients. Surgical informed consent was obtained from either the patients themselves or their family members. As a result, the assessment of blinding of participants and personnel (performance bias) in the Cochrane Collaboration's evaluation, as included in the literature, displayed significant deviation. The primary cause of the increased risk was because these papers discussed the procedure's efficacy, which made it impossible to prevent patients' giving their informed permission to have surgery. As a result, it was difficult to implement the participants' blind technique. Overall, the blind technique was where the high risk was mostly focused. The literature included in this research is generally of excellent quality.

Improvement of motor function in patients with central upper limb paralysis

All three studies compared the effects of CC7 transfer and rehabilitation (n = 192: 192; numbers of RCTs = 41: 37) on the recovery

¹ https://apps.automeris.io/wpd/



of motor ability in patients with central upper limb paresis and chose them for comparative meta-analysis. The studies looked at changes in upper limb Fugl-Meyer scores and range of motion in the surgical and rehabilitation groups (SMD 3.52, 95% CI=3.19–3.84, p <0.00001; Figure 3 and Table 3); (SMD 2.88, 95% CI=2.47–3.29, p <0.00001, P = 73%; Figure 4 and Table 3). The pooled analysis demonstrated that the recovery of upper limb mobility was considerably greater in the paralyzed side of the surgery group than in the rehabilitation group.

Improvement of spasticity in patients with central upper limb paralysis

All studies assessed the impact of CC7 transfer and rehabilitation on the reduction of upper extremity spasticity (n = 192: 192; numbers of RCTs = 41: 37) and were chosen for comparative meta-analysis. The improvement of upper limb spasticity status (MAS) was considerably greater in the surgery group than in the rehabilitation group, according to the pooled analysis (SMD -1.42, 95% CI=-1.60 to -1.25, p < 0.00001, $I^2 = 49\%$; Figure 5 and Table 3).

Adverse events

CC7 transfer's adverse events during short-term follow-up were compared with the rehabilitation group (n=186: 186; numbers of RCTs=35: 31) in two investigations (20, 22). The difference in pain between the two groups was the primary manifestation. Adverse events were more common in the surgical group than in the rehabilitation group but stopped occurring in all patients 6 to 12 months following surgery (RR 4.39, 95% CI=1.04–18.63, p=0.04, I^2 =87%; Figure 6 and Table 1).

TABLE 1 Characteristics of the studies included in the meta-analysis.

Study			Feng et	al. (<mark>20</mark>)ª	Hua et al. (<mark>21</mark>)	Zheng et al (<mark>22</mark>)
Year			20	022	2015	2018
Country			China	/Korea	China	China
Design			RCT	nRCT	RCT	RCT
Age-y			4-	-69	21-34	12-45
The cause of paraly	sis		С	NI	CNI	CNI
Гіme of paralysis-y			È	1	≧1	6-24
Гime of follow-up-	у		:	2	2	1
Number of surger-	7		17	151	6	18
Number of rehabili	tation		13	155	6	18
Outcomes						
The Fugl-Meyer	TT	Surgery	18 ± 4.86	14.82 ± 4.67	17.8±6.37	17.7±5.6
score	Upper-extremity	Rehabilitation	2.08 ± 1.26	2.37 ± 1.82	6±4.2	2.6±2
	- DII	Surgery	-0.95 ± 0.66	-0.87 ± 0.57	-1.34 ± 0.89	-0.83 ± 0.62
	Elbow	Rehabilitation	-0.08 ± 0.28	-0.14 ± 0.57	0.16±0.86	0 ± 0.34
The modified Wris Ashworth scale	7	Surgery	-1.12 ± 0.78	-0.95 ± 0.72	-1.34 ± 0.89	-0.89 ± 0.68
	Forearm	Rehabilitation	-0.23 ± 0.44	-0.20 ± 0.54	0.16±0.86	-0.11 ± 0.47
		Surgery	-1.53 ± 0.8	-1.05 ± 0.7	-1.15 ± 0.74	-0.94 ± 0.64
	Wrist	Rehabilitation	-0.15 ± 0.38	-0.19 ± 0.65	0.02 ± 0.75	-0.17 ± 0.71
		Surgery	-1.59 ± 0.62	-1.34 ± 0.62	-1.34 ± 0.45	-1.17 ± 0.71
	Thumb	Rehabilitation	-0.62 ± 0.77	-0.19 ± 0.47	0.21 ± 0.54	-0.22 ± 0.88
		Surgery	-1.12 ± 0.49	-1.03 ± 0.77	-1.15 ± 0.64	-1 ± 0.69
Fingers 2–5		Rehabilitation	-0.31 ± 0.85	-0.16 ± 0.56	0.21 ± 0.54	-0.17 ± 0.62
Elbow		surgery	35±15.31	30.03 ± 14.79	25±17.61	24 ± 19
	Elbow	Rehabilitation	-3.08 ± 6.3	-4.11 ± 6.14	6.67±10.33	0±3
The range of motion		surgery	39.12 ± 15.64	38.11±16.02	66.67±52.03	36 ± 19
	Forearm	Rehabilitation	-1.54 ± 3.15	-2.32 ± 3.63	5±8.37	1±5
		Surgery	45±15.61	37.81±16.08	88.33±19.41	49 ± 21
	Wrist	Rehabilitation	-2.31 ± 4.39	-2.06 ± 3.95	1.67 ± 4.08	1±5
		Surgery	0/17	0/151	NA	0/18
	Bleeding	Rehabilitation	0/13	0/155	NA	0/18
		Surgery	0/17	0/151	NA	0/18
Adverse events	Infection	Rehabilitation	0/13	0/155	NA	0/18
		Surgery	7/17	91/151	NA	13/18
	Pain	Rehabilitation	2/13	7/155	NA	6/18
	Foreign-body	Surgery	3/17	26/151	NA	12/18
	sensation while swallowing	Rehabilitation	0/13	0/155	NA	0/18
		Surgery	5/17	49/151	NA	15/18
	Fatigue	Rehabilitation	0/13	12/155	NA	0/18
		Surgery	14/17	145/151	NA	16/18
	Numbness	Rehabilitation	0/13	0/155	NA	0/18

The literature of Feng offers patients with RCT and non-RCT studies; the Fugl-Meyer score = the Fugl-Meyer upper extremity scale. It was developed to evaluate stroke rehabilitation. The "shoulder and elbow" and "wrist and fingers" domains make up the scale (total score between 0 and 66, with higher scores reflecting better function); the modified Ashworth scale = each joint, including the elbow, forearm, wrist, thumb, and fingers 2–5 fingers, had its level of spasticity evaluated on a scale from 0 to 5. Higher numbers indicate spasticity levels that are greater; the range of motion = the range of motion in the elbow, forearm, and wrist joints of the paralyzed arm. Higher results suggest improved joint range. Joint mobility was assessed between baseline and post-follow up; adverse events = surgical group adverse events during short-term follow-up and rehabilitation group adverse events. "Data presented as mean.




TABLE 2 Risk of bias assessment for non-randomized-controlled trials.

Domain	Assessment by outcome
	Feng et al. (20)
Bias due to confounding	Low risk
Bias in selection of participants into the study	Low risk
Bias in classification of interventions	Moderate risk
Bias due to deviations from intended interventions	No information
Bias due to missing data	Low risk
Bias in measurement of outcomes	Low risk
Bias in selection of the reported result	Low risk
Overall	Moderate risk

Subgroup analysis

Subgroup analyses investigated differences in study outcomes overall and after removing nRCT. Table 2 illustrates the subgroup analysis findings. The findings of the subgroup analysis indicated that there were no significant differences in the RCTs and nRCTs. In addition, the findings of ROM may play a crucial role in the research of heterogeneity.

Discussion

This meta-analysis assessed the effectiveness and safety of CC7 transfer in the treatment of central upper limb spastic paralysis. The Fugl-Meyer assessment scale and the range of motion of the paralyzed arm indicated a considerable improvement in the motor function of the surgery group, while the modified Ashworth scale revealed a significant reduction in spasticity. Results demonstrated that the upper limb stiffness and motor function were much better in the surgery group. The majority of adverse events in the rehabilitative and surgical groups were pain, and the frequency of adverse events of pain was likely higher in the surgical group (RR 4.39, 95% CI=1.04–18.63, p=0.04, $I^2 = 87\%$; Figure 6 and Table 1). However, long-term monitoring revealed that all negative effects in patients vanished within 6 to 12 months.

Firstly, Gu et al. suggested cross-transposing the contralateral C7 nerve for central upper limb paralysis. The healthy cerebral hemisphere eventually gained control of both upper limbs after the functional rearrangement of the cerebral hemispheres. The paralysis limbs' stiffness and motor function were both improved (23, 24). Numerous articles have analyzed the CC7 transfer's prognosis since its inception, but there has been no consensus on its effectiveness and safety (25, 26). We were the first to employ a more compelling randomized controlled trial in a meta-analysis to investigate the effectiveness and safety of CC7 transfer for central upper limb spastic paralysis. The surgical outcome after CC7 transfer was primarily separated into short-term and long-term outcomes, with the latter being represented in the restoration of motor function in the afflicted limb (27). The literatures that were retrieved from this meta-analysis

Churcher and Crucherer a com		Irgery	Tetel		bilitati			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	lotal	mean	SD	lotal	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.2.1 RCT									
eng-RCT et al 2021	18	4.86	17	2.08	1.26	13	5.9%	4.11 [2.78, 5.44]	
Hua et al 2015	17.8	6.37	6	4.2	3.01	6	3.8%	2.52 [0.85, 4.19]	
Zheng et al 2018	17.7	5.6	18	2.6	2	18	9.0%	3.51 [2.43, 4.59]	
Subtotal (95% CI)			41			37	18.7%	3.50 [2.72, 4.28]	•
Heterogeneity: Tau ² = 0.00	3; Chi ² = 3	2.14, d	f = 2 (P	= 0.34)	; I ² = 7'	%			
Test for overall effect: Z = :	8.80 (P <	0.000	D1)						
3.2.2 nRCT									
eng-nRCT et al 2021)	14.82	4.67	151	2.37	1.82	155	81.3%	3.52 [3.16, 3.88]	
Subtotal (95% CI)			151			155	81.3%	3.52 [3.16, 3.88]	•
Heterogeneity: Not applica	able								
Fest for overall effect: Z = 1		< 0.001	001)						
			,						
otal (95% CI)			192			192	100.0%	3.52 [3.19, 3.84]	•
Heterogeneity: Tau ² = 0.00	D: Chi ² = 0	2.14. d	f = 3 (P	= 0.54)	$ ^{2} = 0$	%			
Fest for overall effect: Z = 3	•			,					-10 -5 0 5 10
Fest for subaroup differen				I (P = 0	96) F:	= 0%			Rehabilitation Surgery
, sector subaroub unforon		0.00	/. w/ = 1	– 0.		0.10			

Forest plot: contralateral C7 nerve transfer improves upper extremity motor function in individuals with spastic paralysis of the upper extremities.

TABLE 3 A summary of the overall data or RCT data for several afflicted limb regions.

Subgroup analysis	к. 1919 - П. С.						
Variables	Studies	Effect size (S	MD, 95% CI)	p-value	l ² %		
		RCTs	RCTs, nRCTs		RCTs	RCTs, nRCTs	
F-M scale		3.50 [2.72, 4.28]	3.52 [3.19, 3.84]	<0.0001	7	0	
Range of motion							
Elbow	3	1.98 [1.00, 2.96]	2.31 [1.42, 3.21]	<0.0001	63	81	
Forearm	3	2.48 [1.59, 3.37]	2.82 [1.99, 3.65]	<0.0001	48	73	
Wrist	3	3.62 [2.61, 4.64]	3.43 [3.11, 3.75]	<0.0001	33	0	
Modified Ashworth s	cale						
Elbow	3	-1.61 [-2.13, -1.08]	-1.34 [-1.56, -1.11]	<0.0001	0	0	
Forearm	3	-1.35 [-1.85, -0.85]	-1.21 [-1.43, -0.99]	<0.0001	0	0	
Wrist	3	-1.46 [-1.98, -0.95]	-1.31 [-1.53, -1.08]	<0.0001	21	0	
Thumb	3	-1.38 [-1.90, -0.87]	-1.73 [-2.35, -1.12]	<0.0001	34	65	
Fingers 2–5	3	-1.31 [-1.81, -0.81]	-1.29 [-1.52, -1.07]	<0.0001	0	0	
Adverse events	3	2.26 [1.20, 4.27]	4.39 [1.04, 18.69]	=0.04	0	87	

*Data presented as mean or median.

	S	urgery		Reh	abilitati	on	:	Std. Mean Difference		Std. N	lean Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, R	andom, 95	% CI	
1.1.1 The Range of Moti	on of Elb	ow					-						
Feng-nRCT et al 2021)	30.03	14.79	151	-4.11	6.14	155	13.5%	3.02 [2.69, 3.35]				-	
Feng-RCT et al 2021	35	15.31	17	-3.08	6.3	13	7.2%	3.02 [1.92, 4.11]			· ·	-	
Hua et al 2015	25	17.61	6	6.67	10.33	6	6.1%	1.17 [-0.10, 2.44]				_	
Zheng et al 2018 Subtotal (95% CI)	24	19	18 192	0	3	18 192	9.6% 36.5%	1.73 [0.95, 2.50] 2.31 [1.42, 3.21]				-	
Heterogeneity: Tau ² = 0.6 Test for overall effect: Z =				P = 0.00)1); l² =	81%							
1.1.2 The Range of Moti	on of Fo	rearm											
Feng-nRCT et al 2021)	38.11	16.02	151	-2.32	3.63	155	13.3%	3.49 [3.14, 3.85]				-	
Feng-RCT et al 2021	39.12	15.64	17	-1.54	3.15	13	6.8%	3.30 [2.15, 4.45]				_	
Hua et al 2015	66.67	52.03	6	5	8.37	6	5.6%	1.53 [0.17, 2.88]					
Zheng et al 2018 Subtotal (95% CI)	36	19	18 192	1	5	18 192	8.7% 34.5%	2.46 [1.57, 3.35] 2.82 [1.99, 3.65]			-	•	
Heterogeneity: Tau ² = 0.4 Test for overall effect: Z =	,	,	,	P = 0.01	l); ² = 7	3%							
1.1.3 The Range of Moti	on of Wr	ist											
Feng-nRCT et al 2021)		16.08	151	-2.06	3.95	155	13.3%	3.42 [3.06, 3.77]				-	
Feng-RCT et al 2021		15.61	17		4.39	13	6.2%	3.79 [2.53, 5.05]					
Hua et al 2015		19.41	6	1.67	4.08	6	1.6%	5.70 [2.70, 8.71]					
Zheng et al 2018	49	21	18	1	5	18	7.9%	3.07 [2.08, 4.07]					
Subtotal (95% CI)			192			192	29.0%	3.43 [3.11, 3.75]				•	
Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =				= 0.39)	; I² = 0%	6							
Total (95% CI)			576			576	100.0%	2.88 [2.47, 3.29]				•	
Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = Test for subaroup differen	= 13.80 (F	< 0.000	001)		,.				-10	-5 Favours [Rehabilitat	0 ion] Favo	5 urs [Surgei	1 [y]

mostly employed F-M and ROM to assess the patients' return to motor function, gauge their capacity to move and the range of motion in their afflicted limbs, and calculate an overall index of curative impact. The outcomes of F-M (SMD 3.52, 95% CI=3.19-3.84, p < 0.00001) and ROM (SMD 2.88, 95% CI=2.47-3.29, p < 0.00001) in the surgery groups were significantly higher than those in the rehabilitation groups, further demonstrating that the surgery had a better impact on

the motor function of the upper limbs in patients with central paralysis. It is important to note that it was reported that the recovery of range of motion for the patient surgery group was significantly different from that of the rehabilitation group. This may be due to the Hua et al. (21) study's small sample size, younger patients who were chosen. Manual assessment of upper limb range of motion may be influenced by subjective factors. This, together with the small

		urgery			abilitati			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV. Random, 95% Cl
2.1.1 MAS Elbow									
Feng-nRCT et al 2021)	-0.87		151	-0.14	0.57	155	11.3%	-1.28 [-1.52, -1.03]	-
Feng-RCT et al 2021	-0.95		17	-0.08	0.28	13	3.3%	-1.59 [-2.43, -0.75]	
Hua et al 2015	-1.34		6	0.16	0.86	6	1.5%	-1.58 [-2.95, -0.21]	
Zheng et al 2018 Subtotal (95% CI)	-0.83	0.62	18 192	0	0.34	18 192	3.9% 1 9.9%	-1.62 [-2.39, -0.86] - 1.34 [-1.56, -1.11]	•
Heterogeneity: Tau ² = 0.0	00: Chi ² =	1.24. c		P = 0.74	(): $ ^2 = 0$				
Test for overall effect: Z =			,	0.1	.,,	,,,,			
2.1.2 MAS Forearm									
Feng-nRCT et al 2021)	-0.95	0.72	151	-0.2	0.54	155	11.3%	-1.18 [-1.42, -0.93]	-
Feng-RCT et al 2021	-1.12	0.78	17	-0.23	0.44	13	3.6%	-1.32 [-2.13, -0.51]	
Hua et al 2015	-1.34	0.89	6	0.16	0.86	6	1.5%	-1.58 [-2.95, -0.21]	
Zheng et al 2018	-0.89	0.68	18	-0.11	0.47	18	4.1%	-1.30 [-2.03, -0.58]	
Subtotal (95% CI)			192			192	20.5%	-1.21 [-1.43, -0.99]	♦
Heterogeneity: Tau ² = 0.0	00: Chi² =	0.49, c	lf = 3 (F	⊃ = 0.92	2); $ ^2 = 0$)%			
Test for overall effect: Z =					,, .				
2.1.3 MAS Wrist									
Feng-nRCT et al 2021)	-1.05	0.7	151	-0.19	0.65	155	11.3%	-1.27 [-1.52, -1.02]	-
Feng-RCT et al 2021	-1.53	0.8	17	-0.15	0.38	13	2.9%	-2.05 [-2.97, -1.14]	
Hua et al 2015	-1.15	0.74	6	0.02	0.75	6	1.5%	-1.45 [-2.78, -0.11]	
Zheng et al 2018	-0.94	0.64	18	-0.17	0.71	18	4.3%	-1.11 [-1.82, -0.41]	
Subtotal (95% CI)			192			192	20.0%	-1.31 [-1.53, -1.08]	◆
Heterogeneity: Tau² = 0.0 Test for overall effect: Z =				P = 0.39	9); ² = ()%			
2.1.4 MAS Thumb									
	1 24	0.62	151	-0.19	0.47	155	10.6%	-2.09 [-2.37, -1.81]	-
Feng-nRCT et al 2021)	-1.34		17	-0.62	0.77	13	3.5%	-1.37 [-2.18, -0.56]	
Feng-nRCT et al 2021) Feng-RCT et al 2021	-1.54	0.62			0.54	6	0.9%	-2.88 [-4.68, -1.07]	
•			6	0.21	0.54				
Feng-RCT et al 2021	-1.59	0.45		0.21 -0.22		18	4.3%	-1.16 [-1.87, -0.45]	
Feng-RCT et al 2021 Hua et al 2015	-1.59 -1.34	0.45	6			18 192	4.3% 19.2%	-1.16 [-1.87, -0.45] -1.73 [-2.35, -1.12]	•
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018	-1.59 -1.34 -1.17 23; Chi² =	0.45 0.71 8.59, c	6 18 192 If = 3 (F	-0.22	0.88	192			•
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2	-1.59 -1.34 -1.17 23; Chi² =	0.45 0.71 8.59, c	6 18 192 If = 3 (F	-0.22	0.88	192			•
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z =	-1.59 -1.34 -1.17 23; Chi² =	0.45 0.71 8.59, c < 0.000	6 18 192 If = 3 (F	-0.22	0.88	192			•
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5	-1.59 -1.34 -1.17 23; Chi ² = = 5.53 (P •	0.45 0.71 8.59, c < 0.000	6 18 192 If = 3 (F 001)	-0.22 P = 0.04	0.88 L); I ² = 6	192 55%	19.2%	-1.73 [-2.35, -1.12]	★
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-nRCT et al 2021)	-1.59 -1.34 -1.17 23; Chi ² = = 5.53 (P -	0.45 0.71 8.59, c < 0.000 0.77 0.49	6 18 192 If = 3 (F 001) 151	-0.22 P = 0.04 -0.16	0.88 I); I ² = 6 0.56 0.85	192 55% 155	19.2% 11.2%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05]	★
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-nRCT et al 2021) Feng-RCT et al 2021	-1.59 -1.34 -1.17 23; Chi ² = = 5.53 (P - -1.03 -1.12 -1.15	0.45 0.71 8.59, c < 0.000 0.77 0.49	6 18 192 If = 3 (F 001) 151 17	-0.22 P = 0.04 -0.16 -0.31	0.88 (); I ² = 6 0.56 0.85 0.54	192 55% 155 13	19.2% 11.2% 3.7%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39]	
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-RCT et al 2021) Feng-RCT et al 2021 Hua et al 2015	-1.59 -1.34 -1.17 23; Chi ² = = 5.53 (P - -1.03 -1.12 -1.15	0.45 0.71 8.59, c < 0.000 0.77 0.49 0.64	6 18 192 If = 3 (F 001) 151 17 6	-0.22 P = 0.04 -0.16 -0.31 0.21	0.88 (); I ² = 6 0.56 0.85 0.54	192 55% 155 13 6	19.2% 11.2% 3.7% 1.2%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39] -2.12 [-3.65, -0.59]	
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-nRCT et al 2021) Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018	-1.59 -1.34 -1.17 23; Chi ² = = 5.53 (P · -1.03 -1.12 -1.15 -1 00; Chi ² =	0.45 0.71 8.59, c < 0.000 0.77 0.49 0.64 0.69 1.22, c	6 18 192 If = 3 (F 001) 151 17 6 18 192 If = 3 (F	-0.22 P = 0.04 -0.16 -0.31 0.21 -0.17	0.88 4); l ² = 6 0.56 0.85 0.54 0.62	192 55% 155 13 6 18 192	19.2% 11.2% 3.7% 1.2% 4.2%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39] -2.12 [-3.65, -0.59] -1.24 [-1.96, -0.52]	
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	-1.59 -1.34 -1.17 23; Chi ² = = 5.53 (P · -1.03 -1.12 -1.15 -1 00; Chi ² =	0.45 0.71 8.59, c < 0.000 0.77 0.49 0.64 0.69 1.22, c	6 18 192 If = 3 (F 001) 151 17 6 18 192 If = 3 (F	-0.22 P = 0.04 -0.16 -0.31 0.21 -0.17	0.88 4); l ² = 6 0.56 0.85 0.54 0.62	192 55% 155 13 6 18 192)%	19.2% 11.2% 3.7% 1.2% 4.2%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39] -2.12 [-3.65, -0.59] -1.24 [-1.96, -0.52] -1.29 [-1.52, -1.07]	
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-RCT et al 2021) Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = Total (95% CI)	-1.59 -1.34 -1.17 23; Chi ² = 5.53 (P - -1.03 -1.12 -1.15 -1 20; Chi ² = = 11.46 (P	0.45 0.71 8.59, c < 0.000 0.77 0.49 0.64 0.69 1.22, c < 0.00	6 18 192 df = 3 (f 001) 151 17 6 18 192 df = 3 (f 0001) 960	-0.22 -0.16 -0.31 0.21 -0.17 P = 0.75	0.88 (1); $ ^2 = 6$ 0.56 0.85 0.54 0.62 (5); $ ^2 = 0$	192 55% 155 13 6 18 192 0% 960	19.2% 11.2% 3.7% 1.2% 4.2% 20.3%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39] -2.12 [-3.65, -0.59] -1.24 [-1.96, -0.52]	
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-RCT et al 2021) Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	-1.59 -1.34 -1.17 23; Chi ² = 5.53 (P - -1.03 -1.12 -1.15 -1 20; Chi ² = = 11.46 (P 206; Chi ² = = 15.93 (P	0.45 0.71 8.59, c < 0.000 0.77 0.49 0.64 0.69 1.22, c < 0.00 37.07, < < 0.00	6 18 192 If = 3 (F 001) 151 17 6 18 192 If = 3 (F 0001) 960 df = 19 0001)	-0.22 P = 0.04 -0.16 -0.31 0.21 -0.17 P = 0.75 0 (P = 0	0.88 (1); $ ^2 = 6$ 0.56 0.85 0.54 0.62 (5); $ ^2 = 0$.008); $ ^2$	192 55% 155 13 6 18 192 0% 960 ² = 49%	19.2% 11.2% 3.7% 1.2% 4.2% 20.3%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39] -2.12 [-3.65, -0.59] -1.24 [-1.96, -0.52] -1.29 [-1.52, -1.07]	-4 -2 0 2 4 Favours [Surgery] Favours [Rehabilitation
Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.2 Test for overall effect: Z = 2.1.5 MAS Fingers2-5 Feng-nRCT et al 2021) Feng-RCT et al 2021 Hua et al 2015 Zheng et al 2018 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau ² = 0.0	-1.59 -1.34 -1.17 23; Chi ² = 5.53 (P - -1.03 -1.12 -1.15 -1 20; Chi ² = = 11.46 (P 206; Chi ² = = 15.93 (P	0.45 0.71 8.59, c < 0.000 0.77 0.49 0.64 0.69 1.22, c < 0.00 37.07, < < 0.00	6 18 192 If = 3 (F 001) 151 17 6 18 192 If = 3 (F 0001) 960 df = 19 0001)	-0.22 P = 0.04 -0.16 -0.31 0.21 -0.17 P = 0.75 0 (P = 0	0.88 (1); $ ^2 = 6$ 0.56 0.85 0.54 0.62 (5); $ ^2 = 0$.008); $ ^2$	192 55% 155 13 6 18 192 0% 960 ² = 49%	19.2% 11.2% 3.7% 1.2% 4.2% 20.3%	-1.73 [-2.35, -1.12] -1.29 [-1.54, -1.05] -1.18 [-1.97, -0.39] -2.12 [-3.65, -0.59] -1.24 [-1.96, -0.52] -1.29 [-1.52, -1.07]	

sample size and the accumulation of risk bias for young patient age, may be a source of heterogeneity in the results.

The alleviation of upper limb spasms was the predominant manifestation of the short-term benefit of CC7 transfer (28). The stretch reflex dysfunction of the central nervous system and muscle spasm were strongly associated. The γ neuron circuit may be reduced and the muscular spasm relieved by successfully cutting the C7 nerve on the side that is afflicted (29). As a result, the amount of alleviation from upper limb spasm may be assessed soon after surgery. The elbow, forearm, wrist, thumb, and fingers 2–5 of the afflicted limb was all thoroughly examined by MAS in the three RCT literatures we chose, and we extracted, analyzed, and assessed the total spasticity alleviation. The CC7 transfer was shown to be effective in reducing the spasticity of the afflicted limb, as evidenced by the suggestion that the MAS in the operation group is considerably lower than that in the recovered group (-1.42, 95% CI = -1.60 to -1.25, p < 0.00001).

The primary side effects of CC7 transfer include postoperative complications, exposure to anatomical channel damage, and impacts on

the healthy upper limb. The middle trunk of the brachial plexus nerve, the C7 nerve, has been shown to include a significant number of motor and sensory neurons. The brachial plexus nerve's superior and inferior trunks may carry out the duties of the transected C7 nerve (30). After transection of the C7 nerve in 694 individuals, Li et al. (31), found no reduction in the strength of the contralateral muscles. Numerous studies have shown that most C7 nerve transfer patients suffered symptoms of numbness in the contralateral limb as well as pain from surgical damage, which went away within 2 weeks to 6 months (9, 27). Pain from the damage caused by the procedure's separation of the nerve and creation of the migration channel is the principal adverse impact described in this article. It is important to note that different anastomoses call for different lengths of the C7 nerve. Some patients needed an alternative anatomic approach, such as an anterior or posterior vertebral approach, or the bridging of additional nerves in order to establish the anastomosis. In two papers, the incidence of adverse events-primarily postoperative pain-in two patient groups was compared. According to the findings, the surgical group had a statistically significant higher rate of adverse

	Surge	ry	Rehabilit	ation		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 New Subgroup							
Feng-RCT et al 2021	7	17	2	13	28.7%	2.68 [0.66, 10.81]	
Zheng et al 2018	13	18	6	18	35.8%	2.17 [1.06, 4.42]	
Subtotal (95% CI)		35		31	64.4%	2.26 [1.20, 4.27]	
Total events	20		8				
Heterogeneity: Tau ² = 0.	00; Chi ² =	0.07, c	lf = 1 (P =	0.79); l ²	= 0%		
Test for overall effect: Z	= 2.52 (P	= 0.01)					
1.1.2 Feng-nRCT et al 2	2021						
Feng-nRCT et al 2021	91	151	7	155	35.6%	13.34 [6.40, 27.84]	
Subtotal (95% CI)		151		155	35.6%	13.34 [6.40, 27.84]	
Total events	91		7				
Heterogeneity: Not appli	cable						
Test for overall effect: Z	= 6.91 (P	< 0.000	001)				
Total (95% CI)		186		186	100.0%	4.39 [1.04, 18.63]	
Total events	111		15				
Heterogeneity: Tau ² = 1.	39; Chi² =	15.77,	df = 2 (P =	= 0.0004); I ² = 87%	0	0.05 0.2 1 5 20
Test for overall effect: Z	= 2.01 (P	= 0.04)					Favours [Rehabilitation] Favours [Surgery]
Test for subaroup differe	nces: Chi	² = 12.8	80. df = 1 (F	P = 0.00	03). I² = 9	2.2%	Favours [Renabilitation] Favours [Surgery]
RE 6							
st plot: relationship bet	ween adv	verse e	vents and	surger	y.		

events than the rehabilitation group (RR 4.39, 95% CI=1.04–18.63, p=0.04), and all adverse events vanished after a year of follow-up. Consequently, CC7 transfer is a safe therapy for central upper limb paralysis.

According to reports, the regeneration rate of human nerve anastomosis was around 1 mm/day (32). One month after surgery, Song et al. observed that nerve regenerated axons developed over the anastomosis. One year after the procedure, the distal end of the upper limb was progressively innervated. Guan et al. (33), observed that the average recovery period for motor function following contralateral C7 nerve anastomosis was more than 1 year. After C7 nerve anastomosis, progressively support the damaged limb's various segments (e.g., elbow, forearm, wrist, etc.). The subgroup study of joint mobility and muscle spasticity recovery in numerous upper extremity locations between the CC7 displacement and therapy groups revealed no significant differences (p < 0.00001). In addition, there was no significant impact of 1 year or 2 years follow-up on the recovery of motor function and myospasm in the afflicted limb in the included studies (p < 0.00001).

The following are limitations of the presented meta-analysis: (1) only 3 studies were included in the meta-analysis, a rather small amount. Further subgroup and sensitivity analyses were challenging to conduct. Because most of the study's participants were from East Asia, the results do not accurately reflect their global applicability. (2) The sample size was modest, despite the fact that all of the chosen papers were RCT and nRCT literatures. Individual variations and confounding variables were present. Specifically, in Hua's et al. (21) paper, the number of patients in the surgery group and the control group was equal at six. Furthermore, the patients were rather young. Due to the limited sample size and large number of confounding variables, it was impossible to do additional research. (3) The damage induced by various surgical methods vary, particularly the exposure and anastomosis of the C7 nerve. For instance, the anterior and posterior spinal approach injured the blood vessels and nerves on the exposure and anastomosis route, resulting in distinct adverse effects. (4) The end index of the study was the score of the score table and the range of mobility of the joint, both of which were susceptible to a substantial subjective effect, and there was a variance in the research findings.

Conclusion

This is the first meta-analysis assessing the effectiveness of CC7 transfer in the treatment of central upper limb spastic paralysis. The effectiveness and safety of CC7 transfer in the treatment of central upper limb spastic paralysis were evaluated in this meta-analysis. Patients in the procedure group had substantially better F-M and ROM scores when measuring their motor function. At the same time, patients in the surgery group had much less muscular spasm, and there were no major adverse responses. The number of patients presented in this research was limited, the follow-up period was brief, and the impact of individual characteristics on prognosis was not ruled out. Therefore, the efficacy of CC7 transfer warranted more investigation and promotion.

Author contributions

WL: the concept and layout of the study, data collecting, analysis, and interpretation, as well as paper writing, data collection, analysis, and interpretation. H-ZZ and ZY: the gathering, analyzing, and interpreting of data. YG and JX: revising the manuscript critically for important intellectual content. H-ZZ: the idea and design of the research, as well as a critical revision of the manuscript's intellectually significant material. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by the Department of Science and Technology of Yangzhou City (Project No. BRA2019026).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. *Lancet Neurol.* (2021) 20:795–820. doi: 10.1016/S1474-4422(21)00252-0

2. Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic brain injury-related emergency department visits, hospitalizations, and deaths—United States, 2007 and 2013. *MMWR Surveill Summ*. (2017) 66:1–16. doi: 10.15585/mmwr.ss6609a1

 Legg L, Drummond A, Leonardi-Bee J, Gladman JR, Corr S, Donkervoort M, et al. Occupational therapy for patients with problems in personal activities of daily living after stroke: systematic review of randomised trials. *BMJ*. (2007) 335:922. doi: 10.1136/ bmj.39343.466863.55

4. Legg L, Langhorne P. Rehabilitation therapy services for stroke patients living at home: systematic review of randomised trials. *Lancet.* (2004) 363:352–6. doi: 10.1016/S0140-6736(04)15434-2

5. Kolcun JPG, Burks SS, Wang MY. Contralateral C7 nerve root transfer restores hand function after central cerebral injury. *Neurosurgery*. (2018) 82:E100–1. doi: 10.1093/neuros/nyy041

6. ChiCtr: The clinical effect of combined pre-operative intensive sensorimotor rehabilitation therapy for chronic stroke patients before the C7–C7 nerve cross transfer: a randomized controlled trial

7. ChiCtr: a randomized controlled trial for contralateral seventh cervical nerve transfer for spastic arm paralysis

8. Ma H, Zheng M, Lu Y, Hua X, Xu W. Cerebral plasticity after contralateral cervical nerve transfer in human by longitudinal PET evaluation. *J Clin Neurosci.* (2018) 48:95–9. doi: 10.1016/j.jocn.2017.10.085

9. Pan X, Zhao G, Yang X, Hua Y, Wang J, Ying Q, et al. Contralateral C7 nerve transfer via the prespinal route in treatment of spastic paralysis of upper limb after cerebral palsy. *Br J Neurosurg*. (2020):1–5. doi: 10.1080/02688697.2020.1859091

10. Li P, Shen Y, Xu J, Liang C, Jiang S, Qiu Y, et al. Contralateral cervical seventh nerve transfer for spastic arm paralysis via a modified prespinal route: a cadaveric study. *Acta Neurochir.* (2020) 162:141–6. doi: 10.1007/s00701-019-04069-y

11. JBT S, Li R, Yan JG, Hyde J, Matloub H. Transhemispheric cortical plasticity following contralateral C7 nerve transfer: a rat functional magnetic resonance imaging survival study. *J Hand Surg Am.* (2013) 38:478–87. doi: 10.1016/j. jhsa.2012.12.018

12. Jiang S, Chen W, Shen YD, Qiu YQ, Yu AP, Xu WD. C7 transfer in a posterior intradural approach for treating hemiplegic upper-limbs: hypothesis and a cadaver feasibility study. *Br J Neurosurg.* (2019) 33:413–7. doi: 10.1080/02688697.2018.1552754

13. Chang J, Wang B, Yu L, Wang T, Sui T, Zhu Y, et al. A cadaver feasibility study of extradural contralateral C7 ventral root transfer technique for treating upper extremity paralysis. *Spine*. (2022) 47:1248–52. doi: 10.1097/BRS.00000000004367

14. Ratican S, Song M, Qiu Y, Su J, Hong J, Xu W. Clinical anatomy of human donor C7 nerve roots for surgical transfer in patients with spastic arm paralysis. *World Neurosurg.* (2021) 153:e213–9. doi: 10.1016/j.wneu.2021.06.087

15. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of observational studies in epidemiology (MOOSE) group. *JAMA*. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. (2009) 339:b2700. doi: 10.1136/bmj.b2700

17. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1113254/ full#supplementary-material

18. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ.* (2016) 355:i4919. doi: 10.1136/bmj.i4919

19. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. *Cochrane Database Syst Rev.* (2019) 10:Ed000142. doi: 10.1002/14651858.ED000142

20. Feng J, Li T, Lv M, Kim S, Shin JH, Zhao N, et al. Reconstruction of paralyzed arm function in patients with hemiplegia through contralateral seventh cervical nerve cross transfer: a multicenter study and real-world practice guidance. *EClinicalMedicine*. (2022) 43:101258. doi: 10.1016/j.eclinm.2021.101258

21. Hua XY, Qiu YQ, Li T, Zheng MX, Shen YD, Jiang S, et al. Contralateral peripheral neurotization for hemiplegic upper extremity after central neurologic injury. *Neurosurgery*. (2015) 76:187–95. doi: 10.1227/NEU.00000000000590

22. Zheng MX, Hua XY, Feng JT, Li T, Lu YC, Shen YD, et al. Trial of contralateral seventh cervical nerve transfer for spastic arm paralysis. *N Engl J Med*. (2018) 378:22–34. doi: 10.1056/NEJM0a1615208

23. Yuan Y, Xu XY, Lao J, Zhao X. Proteomic analysis of trans-hemispheric motor cortex reorganization following contralateral C_7 nerve transfer. *Neural Regen Res.* (2018) 13:331–9. doi: 10.4103/1673-5374.226429

24. Zuo C, Hua X, Guan Y, Xu W, Xu J, Gu Y. Long-range plasticity between intact hemispheres after contralateral cervical nerve transfer in humans. *J Neurosurg*. (2010) 113:133–40. doi: 10.3171/2010.1.JNS09448

25. Bai Y, Han S, Guan J-Y, Lin J, Zhao M-G, Liang G-B. Contralateral C7 nerve transfer in the treatment of upper-extremity paralysis: a review of anatomical basis, surgical approaches, and neurobiological mechanisms. *Rev Neurosci.* (2022) 33:491–514. doi: 10.1515/revneuro-2021-0122

26. Jingyu G, Jun L, Xueqing G, Qiang J, Wenchuan Z. Contralateral C7 nerve transfer through posterior vertebral approach combined with selective posterior rhizotomy of the affected cervical nerve in the treatment of central upper limb spastic paralysis: a case report. *Medicine.* (2021) 100:e25061. doi: 10.1097/MD.00000000025061

27. Wang G-B, Yu A-P, Ng CY, Lei G-W, Wang X-M, Qiu Y-Q, et al. Contralateral C7 to C7 nerve root transfer in reconstruction for treatment of total brachial plexus palsy: anatomical basis and preliminary clinical results. *J Neurosurg Spine*. (2018) 29:491–9. doi: 10.3171/2018.3.SPINE171251

28. Li W, Wang S, Zhao J, Rahman MF, Li Y, Li P, et al. Complications of contralateral C-7 transfer through the modified prespinal route for repairing brachial plexus root avulsion injury: a retrospective study of 425 patients. *J Neurosurg.* (2015) 122:1421–8. doi: 10.3171/2014.10.JNS131574

29. Guan J, Lin J, Guan X, Jin Q. Treatment of central paralysis of upper extremity using contralateral C7 nerve transfer via posterior spinal route. *World Neurosurg.* (2019) 125:228–33. doi: 10.1016/j.wneu.2019.01.181

30. ChiCtr: the clinical effect of combined pre-operative intensive sensorimotor rehabilitation therapy for chronic stroke patients before the C7–C7 nerve cross transfer: a randomized controlled trial. Available at: https://trialsearchwhoint/Trial2aspx?TrialI D=ChiCTR1900027688 (2019).

31. Li WJ, He LY, Chen SL, Lyu YW, Wang SF, Yong Y, et al. Contralateral C7 nerve root transfer for function recovery in adults: a meta-analysis. *Chin Med J.* (2017) 130:2960–8. doi: 10.4103/0366-6999.220316

32. Song J, Qiu WJ, Chen L, Hu SN, Wu JX, Gu YD. Transfers of the ipsilateral C7 plus the spinal accessory nerve versus triple nerve transfers for treatment of C5–C6 avulsion of the brachial plexus. *J Hand Surg Am.* (2020) 45:363.e1–6. doi: 10.1016/j. jhsa.2019.09.010

33. Guan J, Lin J, Guan X, Jin Q, Chen L, Shan Q, et al. Preliminary results of posterior contralateral cervical 7 nerve transposition in the treatment of upper limb plegia after a stroke. *Brain Behav.* (2020) 10:e01821. doi: 10.1002/brb3.1821